Last reviewed · How we verify

VivaVision Biotech, Inc — Portfolio Competitive Intelligence Brief

VivaVision Biotech, Inc pipeline: 0 marketed, 0 filed, 3 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 4 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
VVN461 Ophthalmic Solution 1.0% VVN461 Ophthalmic Solution 1.0% phase 3 Ophthalmology
VVN001 Ophthalmic Solution, 5% VVN001 Ophthalmic Solution, 5% phase 3 corticosteroid Ophthalmology
VVN001 Ophthalmic Solution, Vehicle VVN001 Ophthalmic Solution, Vehicle phase 3 Ophthalmology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Allergan · 1 shared drug class
  2. Balmoral Medical company · 1 shared drug class
  3. Bausch & Lomb Incorporated · 1 shared drug class
  4. Cerium Pharmaceuticals, Inc. · 1 shared drug class
  5. Dr. Reddys Laboratories, SA · 1 shared drug class
  6. Edesa Biotech Inc. · 1 shared drug class
  7. Evon Medics LLC · 1 shared drug class
  8. Federal University of São Paulo · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for VivaVision Biotech, Inc:

Cite this brief

Drug Landscape (2026). VivaVision Biotech, Inc — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/vivavision-biotech-inc. Accessed 2026-05-17.

Related